NASDAQ:COGT Cogent Biosciences Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.93 +0.46 (+6.16 %) (As of 03/5/2021 04:00 PM ET) Add Compare Share Today's Range$7.10Now: $7.93▼$7.9350-Day Range N/A52-Week Range$2.20Now: $7.93▼$52.13Volume719,229 shsAverage Volume300,550 shsMarket Capitalization$153.92 millionP/E RatioN/ADividend YieldN/ABeta3.13 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a Â'bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.Read More HeadlinesCogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021February 18, 2021 | finance.yahoo.comCogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021February 11, 2021 | finance.yahoo.comCogent Biosciences IncDecember 19, 2020 | bloomberg.comCogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional SharesDecember 4, 2020 | finance.yahoo.comCogent Biosciences prices upsized $100M equity offeringDecember 2, 2020 | seekingalpha.comCogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common StockDecember 2, 2020 | finance.yahoo.comCogent Biosciences Announces $60.0 Million Public Offering of Shares of Common StockNovember 30, 2020 | finance.yahoo.comCogent Biosciences Appoints Brad Barnett as Chief Technology OfficerNovember 30, 2020 | finance.yahoo.comCogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual ConferenceNovember 20, 2020 | finance.yahoo.comCogent Bio reports data from PLX9486 combo trial in GIST patientsNovember 18, 2020 | seekingalpha.comCogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020November 18, 2020 | finance.yahoo.comCogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare ConferenceNovember 12, 2020 | finance.yahoo.comCogent Biosciences EPS misses by $4.91November 9, 2020 | seekingalpha.comCogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatesNovember 9, 2020 | finance.yahoo.com38 Stocks Moving In Wednesday's Mid-Day SessionOctober 28, 2020 | msn.comCogent Biosciences appoints Andrew Robbins as CEOOctober 26, 2020 | seekingalpha.comCogent Biosciences Appoints Andrew Robbins as Chief Executive OfficerOctober 26, 2020 | finance.yahoo.comEdited Transcript of COGT earnings conference call or presentation 12-Mar-20 8:30pm GMTMarch 27, 2020 | finance.yahoo.comAndy Frawley Appointed to cogint Board of DirectorsMarch 27, 2020 | www.bloomberg.comEdited Transcript of COGT earnings conference call or presentation 11-Nov-19 9:30pm GMTNovember 13, 2019 | finance.yahoo.comSee More Headlines Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COGT Previous Symbol CUSIPN/A CIK1460329 Webwww.cogint.com Phone561-757-4000EmployeesN/AYear FoundedN/ADebt Debt-to-Equity RatioN/A Current Ratio6.63 Quick Ratio6.63 Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio8.53 P/E GrowthN/A Sales & Book Value Annual Sales$22.50 million Price / Sales6.84 Cash FlowN/A Price / Cash FlowN/A Book Value$4.14 per share Price / Book1.92Profitability EPS (Most Recent Fiscal Year)($4.16) Net Income$-31,830,000.00 Net Margins-264.14% Return on Equity-100.89% Return on Assets-21.22% Miscellaneous Outstanding Shares19,410,000Market Cap$153.92 million Next Earnings Date3/25/2021 (Estimated) OptionableNot Optionable MarketRank™Overall MarketRank™1.26 out of 5 starsMedical Sector824th out of 1,972 stocksPharmaceutical Preparations Industry395th out of 772 stocksAnalyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingCogent Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.50, Cogent Biosciences has a forecasted upside of 120.7% from its current price of $7.93.Amount of Analyst CoverageCogent Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesCogent Biosciences has received 245 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCogent Biosciences has received 200 “underperform” votes. (Add your “underperform” vote.)Community SentimentCogent Biosciences has received 55.06% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cogent Biosciences and other stocks. Vote “Outperform” if you believe COGT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe COGT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 31.50% of the stock of Cogent Biosciences is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cogent Biosciences are expected to decrease in the coming year, from $0.93 to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Receive COGT News and Ratings via Email Sign-up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Cogent Biosciences (NASDAQ:COGT) Frequently Asked Questions Is Cogent Biosciences a buy right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cogent Biosciences stock. View analyst ratings for Cogent Biosciences or view top-rated stocks. What stocks does MarketBeat like better than Cogent Biosciences? Wall Street analysts have given Cogent Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cogent Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Are investors shorting Cogent Biosciences? Cogent Biosciences saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,520,000 shares, an increase of 54.0% from the January 28th total of 987,300 shares. Based on an average trading volume of 488,800 shares, the short-interest ratio is presently 3.1 days. Approximately 2.6% of the company's shares are sold short. View Cogent Biosciences' Short Interest. When is Cogent Biosciences' next earnings date? Cogent Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021. View our earnings forecast for Cogent Biosciences. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) issued its earnings results on Wednesday, November, 8th. The technology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.09. The technology company had revenue of $57.25 million for the quarter, compared to analysts' expectations of $62.24 million. Cogent Biosciences had a negative net margin of 264.14% and a negative trailing twelve-month return on equity of 100.89%. The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.19) EPS. View Cogent Biosciences' earnings history. What price target have analysts set for COGT? 5 analysts have issued 12 month price objectives for Cogent Biosciences' shares. Their forecasts range from $4.00 to $24.00. On average, they expect Cogent Biosciences' share price to reach $17.50 in the next year. This suggests a possible upside of 120.7% from the stock's current price. View analysts' price targets for Cogent Biosciences or view top-rated stocks among Wall Street analysts. Who are Cogent Biosciences' key executives? Cogent Biosciences' management team includes the following people: Mr. Andrew R. Robbins M.B.A., Pres, CEO & Director (Age 45)Mr. John L. Green C.A., CPA, CFO & Principal Accounting Officer (Age 41)Mr. Brad Barnett, Chief Technology OfficerMs. Erin Schellhammer, Chief People OfficerDr. Jessica Sachs M.D., Chief Medical Officer (Age 46) Who are some of Cogent Biosciences' key competitors? Some companies that are related to Cogent Biosciences include Ardelyx (ARDX), Akouos (AKUS), Inventiva (IVA), Clovis Oncology (CLVS), Chimerix (CMRX), IDEAYA Biosciences (IDYA), Flexion Therapeutics (FLXN), Eagle Pharmaceuticals (EGRX), Geron (GERN), Relmada Therapeutics (RLMD), Molecular Templates (MTEM), KalVista Pharmaceuticals (KALV), XBiotech (XBIT), IVERIC bio (ISEE) and AC Immune (ACIU). View all of COGT's competitors. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM). What is Cogent Biosciences' stock symbol? Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT." Who are Cogent Biosciences' major shareholders? Cogent Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (8.91%), Ghost Tree Capital LLC (5.67%), Hillhouse Capital Advisors LTD. (5.15%), Morgan Stanley (4.79%), Atlas Venture Associates IX LLC (4.72%) and Orbimed Advisors LLC (3.37%). View institutional ownership trends for Cogent Biosciences. Which major investors are buying Cogent Biosciences stock? COGT stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Ghost Tree Capital LLC, Hillhouse Capital Advisors LTD., Morgan Stanley, Atlas Venture Associates IX LLC, Orbimed Advisors LLC, BlackRock Inc., and Samsara BioCapital LLC. View insider buying and selling activity for Cogent Biosciences or or view top insider-buying stocks. What is Cogent Biosciences' stock price today? One share of COGT stock can currently be purchased for approximately $7.93. How much money does Cogent Biosciences make? Cogent Biosciences has a market capitalization of $153.92 million and generates $22.50 million in revenue each year. The technology company earns $-31,830,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. What is Cogent Biosciences' official website? The official website for Cogent Biosciences is www.cogint.com. Where are Cogent Biosciences' headquarters? Cogent Biosciences is headquartered at 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. How can I contact Cogent Biosciences? Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The technology company can be reached via phone at 561-757-4000 or via email at [email protected] This page was last updated on 3/5/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
